Bone Biologics Corporation (BBLGW)

Bone Biologics Corporation is a medical device firm dedicated to revolutionizing bone regeneration, particularly within spinal fusion procedures. The company's primary innovation is NELL-1/DBX, a unique combination product featuring an osteostimulative recombinant protein. This bio-engineered protein offers precise, targeted control over new bone formation. Currently, Bone Biologics is advancing the NELL-1/DBX Fusion Device, specifically engineered for spinal fusion applications in skeletally mature patients suffering from degenerative disc disease, focusing on single-level fusions from L4 to S1. Beyond spinal applications, the versatility of its foundational technology promises to deliver improved outcomes across various surgical disciplines, including general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Underpinning its development, the company holds a licensing agreement with the UCLA Technology Development Group to further develop and commercialize NELL-1 for spinal fusion. Established in 2004, Bone Biologics Corporation is headquartered in Burlington, Massachusetts.